Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

25-09-2019 | EMA | News

approvalsWatch

Avelumab indication extended in Europe to advanced RCC

print
PRINT
insite
SEARCH

medwireNews: The EMA has adopted a positive opinion for the first-line use of the PD-L1 inhibitor avelumab in patients with advanced renal cell carcinoma (RCC), in combination with the VEGFR inhibitor axitinib.

The announcement follows the approval of the dual therapy earlier in the year by the US FDA, on the basis of the JAVELIN Renal 101 trial results.

Avelumab has previously been granted approval in Europe for the treatment of metastatic Merkel cell carcinoma.

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

print
PRINT
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Related content

23-03-2018 | Renal cell carcinoma | News

Promising early data reported for avelumab plus axitinib in advanced RCC
Image Credits